Adaptive Biotechnologies (ADPT Quick QuoteADPT - Free Report) reported $71.55 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 21.5%. EPS of -$0.10 for the same period compares to -$0.17 a year ago.

The reported revenue represents a surprise of +7.98% over the Zacks Consensus Estimate of $66.27 million. With the consensus EPS estimate being -$0.13, the EPS surprise was +23.08%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Adaptive Biotechnologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• ClonoSEQ test volume: 36,111 versus the three-analyst average estimate of 34,530.
• Revenue- Total MRD: $66.17 million versus $61.04 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +32.5% change.
• Revenue- Total Immune Medicine: $5.39 million compared to the $5.27 million average estimate based on three analysts. The reported number represents a change of -39.8% year over year.

View all Key Company Metrics for Adaptive Biotechnologies here>>>

Shares of Adaptive Biotechnologies have returned +5% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.